A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04511650 |
Recruitment Status :
Terminated
(After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.)
First Posted : August 13, 2020
Last Update Posted : June 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 Acute Respiratory Distress Syndrome | Drug: Razuprotafib Subcutaneous Solution Drug: Placebo Subcutaneous Solution | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study) |
Actual Study Start Date : | October 21, 2020 |
Actual Primary Completion Date : | February 26, 2021 |
Actual Study Completion Date : | February 26, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Razuprotafib |
Drug: Razuprotafib Subcutaneous Solution
Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
Other Name: AKB-9778 Subcutaneous Solution |
Placebo Comparator: Placebo |
Drug: Placebo Subcutaneous Solution
Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days |
- Proportion of subjects alive and free of respiratory failure at Day 7 [ Time Frame: Baseline up to Day 7 ]
- Proportion of subjects alive and free of respiratory failure at Day 28 [ Time Frame: Baseline up to Day 28 ]
- Length hospitalized and free of respiratory failure from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Length hospitalized and free of respiratory failure from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Length of hospitalization from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Length of hospitalization from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Proportion of subjects who improve by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Proportion of subjects who worsen by at least 2 categories on the NIAID 8-point ordinal scale from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- All-cause mortality at Day 7 [ Time Frame: Baseline up to Day 7 ]
- All-cause mortality at Day 28 [ Time Frame: Baseline up to Day 28 ]
- Length of ICU stay from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Number of subjects in each category of the NIAID 8-point ordinal scale at Day 7 [ Time Frame: Baseline up to Day 7 ]
- Number of subjects in each category of the NIAID 8-point ordinal scale at Day 28 [ Time Frame: Baseline up to Day 28 ]
- Time to return to prehospitalization oxygen requirement [ Time Frame: Baseline up to Day 28 ]
- Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Proportion of subjects who were discharged and remained free of respiratory failure prior to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Change in PaO2:FiO2 ratio from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Change in PaO2:FiO2 ratio from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Number of participants with any serious adverse event from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Number of participants with any treatment emergent adverse event from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Number of participants with any treatment emergent adverse event from baseline to Day 7 [ Time Frame: Baseline up to Day 7 ]
- Number of participants with any serious adverse event from baseline to Day 28 [ Time Frame: Baseline up to Day 28 ]
- Change from baseline in systemic biomarkers of vascular leakage and inflammation (ie, Angpt 2, IL-6, IL-8, TNFα, HMGB-1, CRP and D-dimer); [ Time Frame: Baseline up to Day 7 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ability to understand and provide informed consent;
- Males and non-pregnant females 18 years of age or older at the time of Screening;
- Laboratory-confirmed active SARS-CoV-2 infection within 72 hours prior to randomization, or (if testing results cannot be obtained) by evidence of progressive disease suggestive of ongoing SARS-CoV-2 infection;
- Females of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception through Day 28; and have a negative urine pregnancy test during Screening;
- Currently hospitalized, receiving standard of care therapy for COVID-19, and meets the criteria for moderate or severe COVID-19, as follows: Moderate = symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion and with respiratory rate at 20 or greater breaths/min, SpO2 >93% on room air at sea level, or heart rate at 90 or greater beats/min; Severe = symptoms suggestive of severe systemic illness with COVID-19, which could include any symptom of moderate illness, shortness of breath at rest, or respiratory distress, and respiratory rate at 30 or greater breaths/min, heart rate at 125 or greater beats/min, or SpO2 >93% on room air at sea level or PaO2:FiO2 <300.
Exclusion Criteria:
- Inability to initiate study drug within 12 hours after randomization;
- Female of childbearing potential who is unable or unwilling to forego breastfeeding through Day 28;
- Systolic blood pressure <100 mmHg;
- In shock or requiring pressor support;
- Respiratory failure, defined as subjects who are on mechanical ventilation; are receiving oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20 L/min with fraction of delivered oxygen of 0.5 or greater), noninvasive positive pressure ventilation, or extracorporeal membrane oxygenation (ECMO); or have a clinical diagnosis of respiratory failure (ie, clinical need for 1 of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation);
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × the upper limit of normal (ULN);
- Total bilirubin >2 × ULN;
- Estimated glomerular filtration rate <30 mL/min or receiving hemodialysis or hemofiltration;
- Moribund subject not expected to survive 24 hours in the opinion of the treating clinical team;
- Any concurrent serious medical condition (eg, active malignancies on chemotherapy, post organ transplant, end stage congestive heart failure) or not likely to respond to treatment;
- Decision to withhold life-sustaining treatment; Note: In the event of cardiac arrest, the decision to withhold cardiopulmonary resuscitation only does not fulfill this exclusion criterion.
- Use of cytochrome P450 (CYP) 2C8 substrates (eg, repaglinide, paclitaxel, or cerivastatin) or CYP3A4 substrates (eg, amlodipine, budesonide, dasabuvir, enzalutamide, imatinib, lopinavir, loperamide, saquinavir, sildenafil, midazolam, or montelukast);
- Use of CYP2C8 inhibitors (eg, gemfibrozil, fluvoxamine, or ketoconazole);
- Participation in another investigational study during the present study through the last visit (Day 28); or
- Previous randomization in this study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04511650
United States, California | |
University of Southern California | |
Los Angeles, California, United States, 90033 | |
University of California- Irvine Medical Center | |
Orange, California, United States, 92868 | |
United States, District of Columbia | |
MedStar Georgetown University Hospital | |
Washington, District of Columbia, United States, 20007 | |
United States, Idaho | |
Snake River Research | |
Idaho Falls, Idaho, United States, 83404 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, Ohio | |
University of Cincinnati | |
Cincinnati, Ohio, United States, 45219 | |
United States, Rhode Island | |
Rhode Island Hospital | |
Providence, Rhode Island, United States, 02905 |
Responsible Party: | Aerpio Therapeutics |
ClinicalTrials.gov Identifier: | NCT04511650 |
Other Study ID Numbers: |
AKB-9778-CI-6001 |
First Posted: | August 13, 2020 Key Record Dates |
Last Update Posted: | June 18, 2021 |
Last Verified: | June 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 ARDS Coronavirus SARS-CoV-2 |
COVID-19 Coronavirus Infections Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Acute Lung Injury Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Lung Injury Pharmaceutical Solutions |